PADCEV (enfortumab vedotin) BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)OncologyProduct EnhancementBiologic Phase 1 PF-06414300 project advanced Ulcerative ColitisInflammation & ImmunologyNew Molecular EntitySmall Molecule Phase 1
2Altmetric Metrics Pfizer and Sanofi have each made multi-billion-dollar purchases that widen the scope of their pipelines. Pfizer’s $43 billion acquisition of antibody–drug conjugate (ADC) specialist Seagen gives Pfizer access to Seagen’s linkers, a key part of the technology, and Sanofi’s...
Dansey was chief medical officer of ADC specialist Seagen, which Pfizer acquired for $43 billion last year, and he plans to retire from Pfizer after a new chief oncology officer is appointed. "Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a wor...
Padcev + pembrolizumab is an important growth driver as it has already become the No. 1 prescribed first-line treatment for locally advanced/metastatic urothelial cancer in the U.S. We are expecting potentially registrational interim data this year from ongoing pivotal studies in muscle-invasive ...
With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among th...
InJanuary 2024,Pfizerand Astellas Pharma Inc. (Astellas) announced that theEuropean Medicines Agency(EMA) validated for review a Type II variation application for Padcev, an antibody-drug conjugate (ADC), with Keytruda(8) (pembrolizumab, a PD-1 inhibitor) as a combination th...
(ADC) technology with Pfizer’s scale, expertise and capabilities, we believe we can accelerate breakthroughs in cancer medicines and introduce new solutions to patients around the world. Oncology remains a core therapeutic area for Pfizer, and we believe the proposed acquisition will enhance our ...
Pfizer Inc. reported financial results for the first quarter of 2024 and raised its Adjusted diluted EPS guidance while maintaining all other components of its 2024 financial guidance.
Pfizer. "The addition of Seagen’s world-leading ADC technology will position us at the forefront of innovative cancer care, and strongly complements our existing portfolio across both solid tumors and hematologic malignancies. We believe the combination of our teams, and respective areas of strength...
PADCEV (enfortumab vedotin) BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (Biologic)OncologyProduct EnhancementBiologic Phase 1 PF-06414300 project advanced Ulcerative ColitisInflammation & ImmunologyNew Molecular EntitySmall Molecule Phase 1